Last €2.20 EUR
Change Today -0.027 / -1.21%
Volume 288.5K
COX On Other Exchanges
EN Paris
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

nicox sa (COX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/16/14 - €2.93
52 Week Low
08/6/14 - €1.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NICOX SA (COX)

Related News

No related news articles were found.

nicox sa (COX) Related Businessweek News

View More BusinessWeek News

nicox sa (COX) Details

NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

171 Employees
Last Reported Date: 08/28/14
Founded in 1996

nicox sa (COX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €417.7K
Compensation as of Fiscal Year 2013.

nicox sa (COX) Key Developments

Nicox S.A. Signs Exclusive Distribution Agreement with Nitto Medic for AdenoPlus(R) in Japan

Nicox S.A. announced that it has entered into an exclusive agreement with Nitto Medic for the distribution in Japan of AdenoPlus(R), a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. Nicox has worldwide rights outside North America for AdenoPlus(R) as per an agreement with Rapid Pathogen Screening Inc. Under the terms of the agreement, Nitto Medic will become the exclusive distributor of AdenoPlus(R) in Japan. Nitto Medic will pay a EUR 500,000 upfront payment to Nicox and will purchase the AdenoPlus(R) devices from Nicox. Nitto Medic will be responsible for obtaining the relevant regulatory approval in Japan before launch. AdenoPlus(R) is expected to be launched in Japan within the next 18 months, pending regulatory approval.

Nicox SA Reports Consolidated Earnings Results for the Six Months Ended June 30, 2014

Nicox SA reported consolidated earnings results for the six months ended June 30, 2014. For the six months, the company reported revenues of EUR 2,595,000 compared to EUR 183,000 a year ago. Operating loss was EUR 15,327,000 compared to EUR 9,251,000 a year ago. Loss before income tax was EUR 15,891,000 compared to EUR 9,210,000 a year ago. Net loss was EUR 15,926,000 compared to EUR 9,196,000 a year ago. Net loss attributable to the equity holders of the company was EUR 16,028,000 compared to EUR 9,227,000 a year ago. Basic and diluted loss per share attributable to equity holders of the company was EUR 0.22 compared to EUR 0.13 a year ago. Revenues significantly increased in 2014 driven by the acquisition in December 2013 of Eupharmed Srl and the launch of new products by Nicox's sales force in the U.S and the five major European markets (France, Italy, Germany, Spain and UK). The significant increase in the net loss for the first half of 2014 is consistent with the financial investments made for commercial activities in North America to launch Sjö(TM) and RetnaGene(TM) and in Europe to launch the Xailin(TM) range and to market AdenoPlus(R).

Nicox to Co-Promote Latanoprostene Bunod in US with Bausch + Lomb

Nicox SA announced its decision to exercise rights to co-promote latanoprostene bunod in the US with Bausch + Lomb. According to the terms of a licensing agreement signed by the two companies in 2010, Nicox retains the possibility to co-promote latanoprostene bunod in the US.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €2.20 EUR -0.027

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies

Industry Analysis


Industry Average

Valuation COX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.5x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at